Abstract
Chronic myeloid leukemia (CML) is maintained by leukemic stem cells (LSCs) which are resistant to the existing TKI therapy. Hence a better understanding of the CML LSCs is necessary to eradicate these cells and achieve complete cure. Using the miRNA-gene interaction networks from the CML lin(-) cells we identified a set of up/down-regulated miRNAs and corresponding target genes. Association studies (Pearson correlation) from the miRNA and gene expression data showed that miR-1469 and miR-1972 have significantly higher number of target genes, 75 and 50 respectively. We observed that miR-1972 induces G2-M cell cycle arrest and miR-1469 moderately arrested G1 cell cycle when overexpressed in KCL22 cells. We have earlier shown that a combination of imatinib and JAK inhibitor I can significantly bring down the proliferation of CML lineage negative cells. Here we observed that imatinib and JAK inhibitor I combination restored the expression pattern of the down-regulated miRNAs in primary CML lin(-) cells. Thus effective manipulation of the deregulated miRNAs can restore the miRNA-mRNA networks that can efficiently inhibit CML stem and progenitor cells and alleviate the disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
3' Untranslated Regions / genetics
-
Adaptor Proteins, Signal Transducing / genetics
-
Adaptor Proteins, Signal Transducing / metabolism
-
Base Sequence
-
Cell Lineage / drug effects
-
Cell Lineage / genetics*
-
G1 Phase Cell Cycle Checkpoints / drug effects
-
G1 Phase Cell Cycle Checkpoints / genetics
-
G2 Phase Cell Cycle Checkpoints / drug effects
-
G2 Phase Cell Cycle Checkpoints / genetics
-
Gene Expression Profiling
-
Gene Expression Regulation, Leukemic / drug effects
-
Gene Regulatory Networks* / drug effects
-
Humans
-
Imatinib Mesylate / pharmacology
-
Imatinib Mesylate / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
MicroRNAs / genetics*
-
MicroRNAs / metabolism
-
Neoplastic Stem Cells / drug effects
-
Neoplastic Stem Cells / metabolism
-
Neoplastic Stem Cells / pathology
-
Nuclear Proteins / genetics
-
Nuclear Proteins / metabolism
-
Phosphorylation / drug effects
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Real-Time Polymerase Chain Reaction
-
Reproducibility of Results
-
cdc25 Phosphatases / metabolism
Substances
-
3' Untranslated Regions
-
Adaptor Proteins, Signal Transducing
-
CRKL protein
-
MicroRNAs
-
Nuclear Proteins
-
RNA, Messenger
-
Imatinib Mesylate
-
CDC25B protein, human
-
cdc25 Phosphatases